Belt-Tightening Biogen Looks To Narrow Therapeutic Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Rising Tecfidera sales not enough to offset perceived need for 11% staff cut and pruning of the pipeline, CEO states.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Everest Refocuses After Trodelvy Twist
A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.
China Price-Gouging Includes 'Huge' Sum For Antibiotic
A rare disclosure by China’s national health insurance payer shows how a major state-owned drug maker used its market-dominating position to dodge price-lowering schemes and increase drug prices more than 10-fold.